Durability of Bleeding Protection and Factor IX Activity Levels Are Demonstrated in Individuals with and without Adeno-Associated Virus Serotype 5 Neutralizing Antibodies (Titers <1:700) with Comparable Safety in the Phase 3 HOPE-B Clinical Trial of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B
- Resource Type
- Source
- Blood. 140:4904-4906
- Subject
Immunology Cell Biology Hematology Biochemistry - Language
- ISSN
- 1528-0020
0006-4971